All In Biotech

Drug Trial Radar · NCT06815965

A Clinical Study of Neflamapimod in Patients With Dementia With Lewy Bodies

An Open-Label Phase 2a Clinical Study of the P38 Alpha Kinase Inhibitor Neflamapimod in Patients With Dementia With Lewy Bodies (DLB)

Last checked: Nov 19, 2026Latest source record: Jul 8, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Completed

Status

Completed

Enrollment

26

Actual

Start

Oct 16, 2024

Primary completion

Mar 11, 2026

Study completion Mar 25, 2026

Sponsor

Lead sponsor
EIP Pharma IncIndustry
Sponsor type
Industry
Collaborators
CervoMed, Inc.
First posted
Feb 10, 2025

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Not applicable (single group)
Model
Single group
Masking
None
Primary purpose
Other
FDA-regulated drug
Yes
Who can join
All sexes, from 55 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The purpose of this clinical study is to evaluate the safety and tolerability (side effects) and pharmacokinetics (drug levels in the body) of 80mg neflamapimod given twice daily in patients with dementia with Lewy bodies.

Conditions

  • Dementia With Lewy Bodies (DLB)

Interventions

  • neflamapimodDrug

    Neflamapimod is a highly specific inhibitor of the intra-cellular enzyme mitogen-activated protein kinase 14 (p38α). It is administered orally in 40 mg capsules.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Evaluate the safety and tolerability 80 mg neflamapimod given twice daily in patients with dementia with Lewy bodies.Time frame: From enrollment until the end of treatment at 24 weeks
  2. Evaluate the safety and tolerability of 80mg neflamapimod given twice daily in patients with dementia with Lewy bodies.Time frame: From enrollment until the end of treatment at 24 weeks
  3. Evaluate the maximum plasma concentration (Cmax) of 80mg neflamapimod given twice daily in patients with dementia with Lewy bodies.Time frame: From enrollment until the end of treatment at 24 weeks
  4. Evaluate the trough plasma concentration (Ctrough) of 80mg neflamapimod given twice daily in patients with dementia with Lewy bodies.Time frame: From enrollment until the end of treatment at 24 weeks

Locations

2 sites in 1 country. Site status is shown where the registry gives one.

  • Hôpital Lariboisière - APHP; Centre de Neurologie Cognitive

    Paris, France

  • Strasbourg University Hospital (Les Hopitaux Universitaires de Strasbourg)

    Strasbourg, France

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.